广告
化学
色酮
单胺氧化酶B
铅化合物
单胺氧化酶
药效团
对接(动物)
立体化学
细胞毒性
药理学
体内
体外
生物化学
酶
医学
护理部
生物技术
生物
作者
Francesco Mesiti,Alexandra Gaspar,Daniel Chavarria,Annalisa Maruca,Roberta Rocca,Eva Gil-Martins,Sandra Barreiro,Renata Silva,Carlos Fernandes,Sheraz Gul,Oliver Keminer,Stefano Alcaro,Fernanda Borges
标识
DOI:10.1021/acs.jmedchem.1c00510
摘要
Chromone-3-phenylcarboxamides ( Crom-1 and Crom-2 ) were identified as potent, selective, and reversible inhibitors of human monoamine oxidase B ( h MAO-B). Since they exhibit some absorption, distribution, metabolism, and excretion (ADME)-toxicity liabilities, new derivatives were synthesized to map the chemical structural features that compose the pharmacophore, a process vital for lead optimization. Structure–activity relationship data, supported by molecular docking studies, provided a rationale for the contribution of the heterocycle’s rigidity, the carbonyl group, and the benzopyran heteroatom for h MAO-B inhibitory activity. From the study, N -(3-chlorophenyl)-4 H -thiochromone-3-carboxamide ( 31 ) ( h MAO-B IC 50 = 1.52 ± 0.15 nM) emerged as a reversible tight binding inhibitor with an improved pharmacological profile. In in vitro ADME-toxicity studies, compound 31 showed a safe cytotoxicity profile in Caco-2, SH-SY5Y, HUVEC, HEK-293, and MCF-7 cells, did not present cardiotoxic effects, and did not affect P-gp transport activity. Compound 31 also protected SH-SY5Y cells from iron(III)-induced damage. Collectively, these studies highlighted compound 31 as the first-in-class and a suitable candidate for in vivo preclinical investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI